sglt2 inhibitors and glp-1 receptor agonists together Combining in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy SGLT2 Inhibitors and GLP-1 Receptor
Description
Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini
In 2024, North America led the market, achieving over 49.7% share with a revenue of US$ 26.6 Billion
doi:10.3389/fendo.2020.00478 157
The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study
(2010) High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats
